Effect of Helicobacter pylori infection on deep vein thrombosis seen in patients with Behçet's disease by Sentürk, O et al.
January 2006 EAST AFRICAN MEDICAL JOURNAL 49
East African Medical Journal Vol. 83 No. 1 January 2006
EFFECT OF HELICOBACTER PYLORI NFECTION ON DEEP VEIN THROMBOSIS SEEN IN PATIENTS WITH BEHÇET’S DISEASE
Ö. Sentürk, MD, O. Özgür, MD, S. Hülagü, MD, Department of Gastroenterology, N. Z. Cantürk, MD, Department of General Surgery, Faculty of Medicine,
A. Çelebi, MD and A. T. Karakaya, MD, Department of Gastroenterology, Faculty of Medicine, Kocaeli University, P.O. Box 41900 Sopali, Derince/Kocaeli,
Turkey
Request for reprints to: Dr. Ö. Sentürk, Department of Gastroenterology, Faculty of Medicine, Kocaeli University, 41900 Sopali, Derince/Kocaeli, Turkey
EFFECT OF HELICOBACTER PYLORI INFECTION ON DEEP VEIN THROMBOSIS SEEN IN
PATIENTS WITH BEHÇET’S DISEASE
Ö. SENTÜRK, O. ÖZGÜR. O., S. HÜLAGÜ, N.Z. CANTÜRK, A. ÇELEBI, and A.T. KARAKAYA
ABSTRACT
Objective: To investigate the role of homocysteine metabolism due to Helicobacter pylori
infection on the development of deep vein thrombosis (DVT) in patients with Behcet’s
disease (BD).
Design: Prospective clinical study.
Setting: Teaching hospital.
Subject: Fifty-five patients with BD divided into groups, with DVT and without DVT,
19 healthy individuals and 18 patients with coronary artery disease (CAD) were enrolled
into the study.
Interventions: Plasma homocysteine and Hp seropositivity were determined.
Results: There was significant Hp positivity in all groups (p > 0.05). Homocysteine levels
were not significantly different for each group except patients with CAD (p > 0.05).
Conclusion: There was no difference for frequency of Hp infection in all groups. We
conclude that Hp does not influence DVT seen in BD via homocysteine metabolism,
but the methinnin-loading test would be appropriate for enlighting patients whose fasting
plasma homocysteine levels are found to be normal.
INTRODUCTION
The recognition of Helicobacter Pylori (Hp)
infection as a causative agent of gastritis, peptic ulcer
disease is one of the major discoveries in medicine in
last two decades (1). Hp has also been associated with
a variety of extragastric disease (2,3). Sternby reported
the relationship between the vascular pathology and the
peptic ulcer disease in 1976 (4). Since Hp was
discovered, the relationship between Hp and vascular
diseases has become the point of interest. It has been
discussed whether Hp is an aetiologic factor or a factor
that worsens the course or trigger the diseases of
unknown aetiology such as BD (5,6). In the vascular
form of the BD, the venous involvement is seen more
commonly than the arterial one (7-11).
Mild hyperhomocysteinaemia is an established risk
factor for vascular disease including DVT (12-15).
Although the exact mechanism is not fully understood,
endothelial damage due to leucocytoclastic vasculitis
leading to defective prostacyclin generation or defective
fibrinolysis has been implied in the pathogenesis of
thrombosis in BD (16). Possible role of
hyperhomocysteinaemia on the development of DVT
in BD has not been clarified yet (17-19). As suggested
in a previous study, coagulation abnormality did not
contribute to thrombotic complications and
hyperhomocysteinaemia may play a role in the
hypercoagulability of BD patients (17). Even though
there was no other study supporting this suggestion,
Sung and Sanderson (20) have proposed that Hp
infection predisposes to hyperhomocysteinaemia through
utritional deficiencies of folate, vitamine B6 and B12.
In this study, incidence of Hp infection and the
possible association between development of DVT in
BD and the Hp infection was investigated to reveal the
cause or a potential triggering effect of Hp infection
on the development the venous thrombosis in patients
with the BD.
MATERIALS AND METHODS
Fifty five patients with BD (25 men, 30 women; mean
age 37, 95± 1.25; range 18-61 year old), were enrolled into
the study. The diagnosis was based on the decision of an
experienced clinician according to the criteria of the
International Behçet’s Study Group (21). The patients were
divided into two groups including with (19 patients) and
without (36 cases) DVT. Nineteen healthy volunteers and 18
patients with CAD were also enrolled as a control group.
A senior clinician and radiologist diagnosed the DVT
by the colored Doppler ultrasound (Toshiba Eccocee, Japan)
in addition to the clinical and the laboratory evaluations.
Diagnostic criteria for colour-coded duplex sonography was:
visualisation of an intraluminal thrombus in a deep vein; lack
of or incomplete compressibility; absence of flow
spontaneously and following distal manipulation.
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Five millilitres of venous blood was drawn in the
morning under standardised conditions. Within 30 minutes,
the blood was centrifuged and immediately divided into
aliquots. Specific anti-Hp Ig G were measured by “Helicobacter
Pylori Double Spot Test” (Medisera Diagnostics, Annacis
Biolab Ltd., Canada) according to manufacturer’s instructions.
Sensitivity and specifity for this method were 96% and 95%
respectively(22). Plasma homocysteine levels were measured
by fluorescence polarisation immunoassay technology (FPIA)
(Abbot GmBH Diagnostika Max- Planck-Ring2 D-65205
Wiesbaden Delkenheim, Germany). Normal range of the kit
was 5-15µmole/l.
Data are presented as the mean ± SD. Statistical analysis
was performed by an IBM computer with the use of Statistical
Package of Social Science ver. 9.0 (SPSS ver. 9.0). Differences
of frequencies of Hp were tested with the X2 test or Fisher’s
exact test. Kruskal- Wallis method was used to determine the
differences between the groups. The comparison between the
measured homocysteine levels was made by using one- way
variance analysis (ANOVA). p<0.05 was considered
statistically significant.
RESULTS
Helicobacter pylori (Hp) was positive in 15 of the
19 patients (%78.9) with DVT. The mean total
homocysteine levels were 11.67±0.88 µmole/L in
patients with BD. There was not significant differences
for homocysteine levels between patients with and
without Hp infection (p>0.05) (Table 1). Hp was
positive in 27 (75.0%) of the 36 patients with BD and
without DVT. It was negative in nine (25.0%) of them.
The mean homocysteine levels were 10.97±0.58 µmole/
l in this group. Homocysteine levels between patients
with and without Hp, who had no DVT, was not also
significantly different (p>0.05) (Table 1). Hp was
positive in 13 (68.4%) of the healthy control group.
Hp was 77.8% positive in 18 patients with CAD. There
was also no significant differences for homocysteine
levels between Hp positive and negative in either
healthy controls or patients with CAD (p>0.05) (Table
1). There were no significant differences for Hp
seroprevalence among all groups (p>0.05). On the other
hand, mean homocysteine levels in patients with CAD
was significantly higher than the others (p<0.05).
DISCUSSION
In this study, we have determined that there was
no significant difference for Hp seropositivity among
groups including BD. Mendall et al. (23) have reported
the possible association between Hp infection and
coronary heart disease. In a meta analysis, Danesh and
Peto (24) reported that there was no relationship
between the Hp seropositivity and the vascular diseases.
Avci et al. (25) suggested that Hp seroprevalence
between patients with BD and controls did not show
significant difference, but the number and the size of
oral and genital ulcers decreased and the clinical
manifestations regressed with the eradication of Hp.
These findings suggest that Hp infection may be one
of the triggering factors which induce immunological
phenomena in the pathogenesis of BD. On the other
hand, in that study, there was no data about DVT. In
the present study, we did not determine any significant
differences for Hp seroprevalence between DVT positive
and negative patients with BD. However, it is difficult
to say that Hp does not play a role in the aetiology
of DVT in patients with BD because high Hp
seroprevalence in Turkey may mask the possible relation.
Several mechanisms have been proposed for how
Hp might increase CAD risk (26). Sung and Sanderson
(20) hypothesised to prove that Hp gastritis could cause
vitamin B deficiency, leading to hyperhomocysetinaemia
and thus increased risk of CAD. Wilcken and Wilcken
(27) suggested that homocysteine metabolism may
contribute to the pathogenesis of some cardiovascular
diseases of young adults. There were various reports
about association of arterial disease and
hyperhomocysteinaemia, but the relation between
homocysteine level and development of venous
thromboembolism is still in debate (28-31). Although
the relationship between hyperhomocysteinaemia and
venous thrombosis has been shown by epidemiological
data (12,26), the pathophysiology has not been clarified
yet. In a prospective study by Ridker et al.(32),
homocysteine levels were found to be high before the
thrombotic event and it was suggested that
hyperhomocysteinaemia must be considered as a causal
Table 1
Demographic and clinical characteristics of total groups
BD BD Healthy Controls
with DVT without DVT Controls With CHD
No (n) 19 36 19 18
Female/Male 10/9 20/16 7/12 8/10
Age mean (year) 39.11 37.33 34.16 56.83
H. pylori positivity (%) 15(78.9) 27(75) 13(68.4) 14(77.8)
Mean plasma 11.67 10.97 11.43 16.43
homocysteine
levels(µmol/L)
(BD = Behçet’s disease, DVT = Deep venous thrombosis, CAD = Coronary artery disease, CG = Control group)
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factor in venous thrombosis. The results of a previous
study suggested homocysteine levels were not elevated
in BD when compared with the healthy controls (33).
In our study, homocysteine levels were not significantly
different among groups except control patients with
CAD. On the other hand, homocysteine levels in
patients with BD with and without DVT and in healthy
control group can not suggest that the homocysteine
metabolism is intact, because we measured only fasting
plasma homocysteine levels but methionin loading test
was not performed.
Finally, although there is no effect of Hp on DVT
seen in BD through homocysteine metabolism in our
study, it can not suggest that the homocysteine
metabolism is intact. The methionin loading test would
be appropriate to this subject at least for patients whose
fasting plasma homocysteine levels are in normal range.
Further studies are needed to clarify the clinical
implication of this situation.
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